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Abstract
Background: Adrenomedullin (ADM), a novel vasorelaxant peptide, was found in human/rat ovaries and uteri.
Plasma ADM level increases in pregnant women and pregnant rats.
Methods: The gene expression levels of Adm and its receptor components - Crlr, Ramp1, Ramp2 and Ramp3, the
ADM peptide concentration and localization in the rat female reproductive system during gestation were studied
by real-time RT-PCR, EIA and immunohistochemical techniques.
Results: The mRNAs of Adm and its receptor component and ADM were differentially distributed between
implantation sites and inter-implantation sites of the pregnant uterus. The day on which vaginal sperm were found
was taken to be pregnancy day 1. The Adm mRNA levels in the implantation sites of the uteri in mid- (day 12) and
late pregnancy (day 17) were more than 10-fold higher than those in nonpregnancy, pre-implantation (day 3) or
early (day 7) pregnancy. ADM was localized in the endometrial stroma with increased immunoreactivity from
nonpregnancy to pregnancy. The ADM level and the mRNA levels of Adm, Crlr, Ramp2 and Ramp3 in the corpus
luteum all increased in late pregnancy compared with early pregnancy. The gene expression of Adm and it
receptor components and intense immunostaining of ADM were also found in the oviduct during pregnancy.
Conclusions: The gene expressions levels of Adm and its receptor components - Crlr, Ramp1, Ramp2 and Ramp3,
and ADM peptide concentration exhibited a spatio-temporal pattern in the rat female reproductive system during
gestation and this suggests that ADM may play important roles in gestation.
Background
Adrenomedullin (ADM) was a novel potent vasodilator
first discovered in human pheochromatocytoma tissue in
1993 [1]. The Adm gene and its protein product are
highly conserved across species, including human, rat,
pig and cow [2-5]. It is a member of the calcitonin family
with a high sequence homology to calcitonin gene-related
peptide (CGRP). It consists of 52 amino acids in human
and 50 amino acids in the rats [2,3]. ADM can bind to
the CGRP receptor in several types of tissues [6,7], but
specific ADM receptors that are insensitive to CGRP
receptor antagonist have been identified [8]. McLatchie
et al. [9] demonstrated that the combination of calcitonin
receptor-like receptor (CRLR) and receptor activity-
modifying protein (RAMP) isoforms determines the
ligand selectivity for CGRP and ADM. Coexpression of
CRLR with RAMP1, RAMP2 and RAMP3 produces the
CGRP, the ADM1 and ADM2 receptors respectively.
ADM is synthesized and secreted by various organs and
tissues, including the heart, kidney, lung, adrenal gland
and reproductive organs, such as the ovary [10-14], the
uterus [10,15], the oviduct [14], the testis [16-19], the
prostate [20,21], and the epididymis [22]. Since its discov-
ery as a potent vasodilator, there have been extensive stu-
dies on the pleiotropic effects of ADM [23-26].
Remarkable increases in plasma ADM concentrations
were reported in both in human [27] and the rat [28] dur-
ing pregnancy. ADM found in granulosa cells enhances
progesterone production in human [13] and suppresses
FSH-stimulated granulosa cell differentiation in the rat
[11] by an autocrine action. The increases in ADM expres-
sion and binding sites in the rat uterus in late gestation
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any medium, provided the original work is properly cited.[15] may be related to the inhibitory role of ADM in uter-
ine contractility [15,29]. The infusion of an ADM antago-
nist (hADM22-52) during early or late gestation in the
rats caused fetoplacental growth restriction [30,31]. The
Adm-/- mice are non-viable [32-34]; and the haploinsuffi-
cient (Adm+/-) female mice were reported to have
reduced pregnancy success [35], in support of a highly
essential role for ADM in gestation especially in fetal
growth and development. The expression of ADM and its
receptors in the ovary and the oviduct of the cycling rats
has been studied by our group and ADM was found to
inhibit FSH-induced estradiol secretion from follicles and
eCG-stimulated progesterone release in corpora lutea [14].
We hypothesize that the distribution and levels of ADM
and its receptors may change at different stages of preg-
nancy according to the roles of ADM. The expression of
ADM and its receptors in the uterus, the oviduct and the
corpus luteum in the rats of early, mid- or late pregnancy
was therefore studied for possible physiological roles of
ADM during gestation.
Methods
Animals
Mature Sprague-Dawley rats (12-13 week old) were
obtained from the Laboratory Animal Unit, LKS
Faculty of Medicine, the University of Hong Kong.
Female rats showing three consecutive regular oestrous
cycles were included in this study. The rats were
housed at a constant temperature, humidity, under a
12-hour light-dark cycle (dark period 07:00 h to
19:00h) and rat chow and water were available ad libi-
tum. Proestrus females were caged with proven fertile
males overnight. The presence of vaginal sperm the
following morning was taken evidence of pregnancy
and this was day 1 of pregnancy. Rats of pre-implanta-
tion, early, mid- and late pregnancy were killed on
days 3, 7, 12 and 17 of gestation. Pseudopregnant
females obtained by mating with vasectomized male
rats were also killed on day 7 of pseudopregnancy.
Diestrus females were killed as nonpregnant controls.
The uteri were dissected and implantation sites and
inter-implantation sites were separated on days 7, 12
and 17 pregnancy. The foetuses and placentae of day
12 and 17 pregnant rats were collected before the dis-
section of the uteri. The ovaries were collected and the
corpora lutea were isolated under a dissecting micro-
scope using two 26G syringe needles. The oviducts
were also collected and all the tissues were snap-frozen
in liquid nitrogen and stored at -80°C for further ana-
lysis. Freshly collected intact uteri, ovaries and oviducts
were fixed in neutral buffered formalin for immunohis-
tochemical study. All procedures were approved by the
Committee on the Use of Live Animals for Teaching
and Research, the University of Hong Kong.
Genes expression of Adm, Crlr, Ramp1, Ramp2 and Ramp3
Total RNA of the uterus, corpus luteum, oviduct, foetus
and placenta were extracted using TRIZOL reagent and
subjected to real-time RT-PCR analysis. RNA samples
(1 μg) were reverse transcribed into cDNA with the
iScript reverse transcriptase according to the manufac-
turer’s instructions (Bio-Rad Laboratories, Hercules,
CA). The real-time RT-PCR technique has been pre-
viously described [15]. Standard curves for each primer
pair were prepared using serial dilution of the cDNA to
determine PCR efficiency. The PCR efficiencies for
Adm, Crlr, Ramp1, Ramp2, Ramp3 and Actb were all
a b o v e0 . 9 5a n ds i m i l a r .T h er e l a t i v eg e n ee x p r e s s i o n
levels normalized to Actb were analyzed using the
ΔΔCT method, where CT was the cycle threshold. The
reaction mixtures contained 25 μl iQ SYBR Green
Supermix (Bio-Rad Laboratories, Hercules, CA), 500 nM
of each primer, 1 μlt e m p l a t ec D N A ,a n dD N a s e - f r e e
water to a final volume of 50 μl. Cycle conditions were
95°C for 10 min, followed by 40 cycles of 95°C for
45 sec, 59°C for 30 sec, and 72°C for 45 sec. The reac-
tion was completed with a dissociation step for melting
point analysis from 50°C to 95°C (in increments of 0.5°C
for 10 sec each. The primers were designed on the basis
of the published sequences of Adm (caggacaagcagag-
cacgtc, forward; tctggcggtagcgtttgac, reverse); Crlr
(ccaaacagacttgggagtcactagg, forward; gctgtcttctcttt-
ctcatgcgtgc, reverse); Ramp1 (cactcactgcaccaaactcgtg, for-
ward; cagtcatgagcagtgtgaccgtaa, reverse); Ramp2
(aggtattacagcaacctgcggt, forward; acatcctctgggggatcggaga,
reverse); Ramp3 (acctgtcggagttcatcgtg, forward; actt-
catccggggggtcttc, reverse) and Actb (ggaaatcgtgcgtgacatta,
forward; aggaaggaaggctggaagag, reverse). Melt curve ana-
lysis for each primer set revealed only one peak for each
product. The size of the PCR products was confirmed
by comparing the size of the product with a commercial
ladder after agarose gel electrophoresis.
Immunocytochemistry (IHC)
Immunohistochemistry was performed on 5 μm sections
of paraffin-embedded tissues with a peroxidase-labeling
kit (Vector Laboratories, Burlingame, CA). The anti-
serum against rat ADM (Phoenix Pharmaceuticals,
Burlingame, CA) was used at a final dilution of 1:500.
Staining was visualized using a DAB substrate kit for
peroxidase (Vector Laboratories, Burlingame, CA). The
antibody was omitted from control sections to check for
nonspecific staining.
Extraction of ADM from the uterus, ovary, oviduct, foetus
and placenta
Tissues including the uterus, corpus luteum, oviduct,
foetus and placenta were homogenized in 2N ice-cold
acetic acid and then boiled for 10 min. A 50 μla l i q u o t
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tories, Hercules, CA). The remaining homogenates were
centrifuged at 18, 600 × g for 20 min at 4°C. The super-
natants were lyophilized and stored at -20°C.
ADM Enzyme Immuno Assay (EIA)
The lyophilized tissue samples were reconstituted in 1X
ADM EIA assay buffer. ADM peptide concentrations
were measured in duplicates using an ADM (1-50) (rat)
EIA kit (Phoenix Pharmaceuticals, Burlingame, CA). The
minimum detectable concentration was 0.15 ng/ml and
the range was 0-100 ng/ml. The intra-assay and inter-
assay errors were less than 5% and 14% respectively.
Statistical analysis
The data are expressed as mean ± SEM. When there was
only one variable, One-way ANOVA with the Fisher’s
Least Significance Difference post-hoc test was employed.
When there were two variables, 2-way ANOVA was used.
The significance level was set at P < 0.05.
Results
Expression of Adm and its receptor components in the
uterus, foetus, placenta, corpus luteum and oviduct
during pregnancy
The results for the mRNA levels of Adm and its recep-
tor components, Crlr, Ramp1, Ramp2 and Ramp3 were
shown in Figure 1. In the uterus, Adm was differentially
expressed between implantation and inter-implantation
sites. Adm mRNA levels at the implantation sites of
mid- (12-day) and late (17-day) pregnant rats were
much higher than those of the inter-implantation sites
(Figure 1A), which had values similar to those in the
uteri of nonpregnant, pre-implantation (3-day) and early
(7-day) pregnant rats (Figure 1A). The Adm mRNA
levels of the uteri from the pseudopregnant rats were
80% of those from the nonpregnant rats (0.80 ± 0.10,
n = 11 vs 1.00 ± 0.08, n = 14) and the values were not
significantly different. There were also increases in Crlr
(Figure 1B) and Ramp1 (Figure 1C) mRNA levels in
implantation sites at late pregnancy compared with early
pregnancy. For the Ramp2 (Figure 1D) and Ramp3
(Figure 1E) mRNA levels, there was a trend for a
decrease from early to late pregnancy in both the
implantation and inter-implantation sites. The mRNA
levels of ADM receptor component proteins were also
differentially expressed (Figure 1B-E). During early preg-
nancy, the expression levels of Crlr, Ramp1 and Ramp2
were all higher at inter-implantation sites than implanta-
tion sites (Figure 1B-D) and the reverse was true for
Ramp3 (Figure 1E). During late gestation, the relative
expression levels of C r l r ,R a m p 1 ,R a m p 2and Ramp3
between implantation sites and inter-implantation sites
were opposite to those in the early gestation, with
higher levels of Crlr, Ramp1 and Ramp2 at implantation
sites (Figure 1B-D) and higher Ramp3 level at inter-
implantation sites (Figure 1E). During mid-gestation, the
expression levels of both Crlr and Ramp3 at the implan-
tation sites were higher than inter-implantation sites
and that of Ramp1 were lower at the implantation sites
(Figure 1B-E).
T h eg e n ee x p r e s s i o nl e v e l so fAdm, Ramp1 and
Ramp3 o ft h ep l a c e n t aw e r eh i g h e rt h a nt h o s eo ft h e
foetus in both mid- and late gestation (Figure 2). The
mRNA levels of Adm and Ramp3 in the placenta were
higher in mid-gestation than in late gestation. The foe-
tus had a higher Adm, Crlr, Ramp1 and Ramp3 mRNA
levels in late gestation than mid-gestation (Figure 2).
In the corpus luteum (Figure 3), the Adm mRNA
levels were dramatically increased in mid- and late
gestation. The mRNA levels of receptor components
Crlr, Ramp2 and Ramp3 in late gestation were also ele-
vated. The mRNA levels of Ramp3 showed a continual
increase from nonpregnancy to late gestation.
In the oviduct (Figure 4), the expression levels of Adm
decreased from pre-implantation to late pregnancy. The
expression levels of Crlr were much lower from early to
late gestation than pre-implantation. There was no sig-
nificant difference in the expression levels of Ramp1,
Ramp2 or Ramp3.
ADM peptide levels in the uterus, foetus, placenta, corpus
luteum and oviduct during pregnancy
In the uterus, ADM was differentially distributed between
the implantation sites and inter-implantation sites in
both early and late gestation (Figure 5A). While there
was no differences between the uterus samples from non-
pregnant (234 ± 12 pg/mg protein, n = 15) and pseudo-
pregnant (230 ± 19 pg/mg protein, n = 12) rats, the
ADM level was higher in inter-implantation sites than
implantation sites in early and mid-pregnancy and the
opposite was true in late pregnancy (Figure 5A). Overall,
the inter-implantation sites in early pregnancy had the
highest level of ADM peptide. The ADM levels in the
inter-implantation sites in early pregnancy declined at
mid- and late pregnancy. The foetuses from mid-preg-
nant rats showed a higher ADM level than the placentae
from mid-pregnant rats (Figure 5B). The placental ADM
levels decreased from mid-gestation to late gestation
(Figure 5B). The ADM levels in the corpora lutea of non-
pregnant and late pregnancy rats were higher than those
from early and mid-pregnant rats (Figure 5C). The ADM
levels of the oviduct were higher at pre-implantation and
decreased in late pregnancy (Figure 5D).
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reproductive system
The nonpregnant uterus showed ADM positive staining
at endometrium (Figure 6A) and weak staining at myo-
metrium and serosa (data not shown). The uteri of early
pregnant (7-day) rats with implanted embryos showed
heavier ADM staining than those of nonpregnant rats,
especially in the decidua (Figure 6B). The embryo was
also positive for ADM (Figure 6D). In the endometrium,
ADM staining was also found in the luminal epithelium
Figure 1 Expression of Adm and its receptor components in the uterus from early, mid- and late pregnant rat.E x p r e s s i o no fAdm (A),
Crlr (B), Ramp1 (C), Ramp2 (D) and Ramp3 (E) in the uterus from nonpregnant rats and rats of different pregnancy stages. Data were presented
as mean ± SEM. n = 3 for nonpregnancy, and pre-implantation, n = 6 for implantation sites and inter-implantation sites of early, mid- and late
pregnancy.
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the endothelial lining of the blood vessels (Figure 6F).
In the ovary from the nonpregnant rats, ADM positive
staining was localized to interstitial cells, ovum, cumulus
oophorus and granulose cells of the follicles (Figure 7A)
and luteal cells of the corpus luteum (Figure 7B). In the
pregnant rats, the majority of the ovarian volume was taken
up by the growing corpora lutea, which were also the main
location of ADM staining. There was no obvious difference
in the density of ADM staining in the corpus luteum from
nonpregnant rats to pregnant rats (data not shown), though
there was heavy ADM staining at the centre of some cor-
pora lutea from late pregnant rats (Figure 7C).
In the oviduct, intense ADM staining was localized in
the mucosal layer of the oviduct, especially in the
ciliated epithelium from nonpregnant and pregnant rats
(Figure 7D). The muscularis and serosa layers of the ovi-
duct showed little ADM staining.
There was no staining in the negative controls (see
Additional file 1, Figure S1).
Discussion
To the best of our knowledge this is the first time course
study of ADM and its receptor component proteins in
pregnancy in the female reproductive tract and corpus
luteum. In our previous study in the rat, the oviduct
expressed the highest level of ADM in the female repro-
ductive tract during the oestrous cycle [14]; but ADM and
its mRNA have not been characterized in the pregnant
rats. ADM was most intense in the ciliated epithelium.
CGRP is known to inhibit contractility in the human ovi-
ducts [36] and CGRP-binding sites are found on the vas-
cular smooth muscle cells [37]. Endothelin 2 has been
shown to stimulate oviductal contraction in the rat [38]
and ADM may inhibit this effect (Liao, Ho, Tang and O,
unpulished data). Recently, we have also demonstrated
that the presence of sperm in the oviduct stimulates ADM
production, which in turn stimulates ciliary beating in the
rat [39] and human [40] oviducts. During pregnancy, the
increase in ADM peptide in the pre-implantation period
may be related to the presence of sperm in the oviduct as
Figure 2 Expression of Adm and its receptor components in the foetuses and placentae.E x p r e s s i o no fAdm, Crlr, Ramp1, Ramp2 and
Ramp3 in the foetuses and placenta from mid- and late pregnancy. Data were presented as mean ± SEM. n = 6-8 for foetus, n = 6 for placenta.
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which facilitate the ova/embryo transportation into the
uterus. The decreases in ADM peptide and Adm mRNA
levels in late pregnancy and in Crlr mRNA in mid- and
late pregnancy may indicate that this inhibition is less
important after placenta formation.
The most dramatic changes in ADM peptide and
mRNA expression occurred in the uterus during preg-
nancy. Both the Adm mRNA and ADM were differentially
distributed between implantation and inter-implantation
sites. The lack of a difference in Adm mRNA levels and
ADM peptide levels between the nonpregnant uterus and
the pseudo-pregnant uterus suggests that such changes in
the implantation sites must be due to the contact between
the embryo and the uterus instead of alterations in hor-
mone levels in the systemic circulation. In early gestation,
ADM levels and mRNA levels of Crlr, Ramp1,a n dRamp2
in the inter-implantation sites were higher than in implan-
tation sites, in line with a role for ADM to increase blood
supply [41] and to inhibit uterine contractility [42]. Adm
mRNA levels in the implantation sites of the uteri from
mid- and late pregnant rats were much higher than the
inter-implantation sites. The differences were much less
marked in ADM peptide levels, suggesting a possible
increase in release. An increase in Adm mRNA level in the
uteri of pregnant rats has been previously reported [14].
Plasma ADM levels are elevated in pregnant rats [28,43]
and pregnant women [27], presumably due to secretion
by the uterus [14,41] for the adaptation of the vascular
s y s t e mt op r e g n a n c y[ 4 4 ] .T h ev e r yh i g hl e v e lo fAdm
mRNA and high levels of Crlr and Ramp1 mRNA at late
pregnancy suggests an increasingly important role of
ADM towards term.
T h eg e n ee x p r e s s i o nl e v e l so fCrlr and Ramp1 were
higher at the implantation sites of late pregnancy than
those in the uteri of nonpregnant rats, in line with a
previous report of an increase in ADM binding sites in
late pregnancy [14]. This change may increase the num-
ber of CGRP receptors and augment the action of
ADM, the expression of which was also increased. It is
pertinent to note that ADM has been shown to inhibit
uterine contraction via the CGRP receptor [14]. The
increase in Crlr and Ramp1 gene expression from early
to late pregnancy is also in line with the increase in
CGRP receptor binding from day 7 of gestation [45].
CGRP is found in the nerves in the uterus [46] and
Figure 3 Expression of Adm and its receptor components in the corpus luteum from early, mid- and late pregnant rat. Expression of
Adm, Crlr, Ramp1, Ramp2 and Ramp3 in the corpus luteum from nonpregnant rats and rats of different pregnancy stages. Data were presented
as mean ± SEM. n = 3.
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tion of the uterine artery [48].
Active angiogenesis is observed during early to mid-
pregnancy to meet the need for an increase in blood
supply [49]. ADM have been proposed to exhibit its
pro-angiogenic actions through CRLR/RAMP2 and
CRLR/RAMP3 receptors [50] or CRLR/RAMP2 receptor
[51]. The high Crlr, Ramp2 and Ramp3 expression levels
in the uterus in early and mid-pregnancy might contri-
bute to the increased action of ADM in angiogenesis.
Immunohistochemical study showed that ADM were
located mainly in the endometrial stroma, similar to the
finding of Cameron et al. [10,52]. In our study, a trend
for an increase in ADM immunoreactivity was observed
from nonpregnant uterus to the pregnant uterus. The
nonpregnant and 3-day pregnant uteri showed limited
ADM staining in the epithelial cells lining the uterus
while in early pregnancy, stronger staining was localized
not only in the epithelium, but also in the blood vessels.
The intense ADM immunostaining in the blood vessels
suggests both an angiogenic role [42] and a vasodilatory
role [43] in the endometrial blood vessels for increasing
blood supply. ADM may have multiple roles in the
uterus, regulating angiogenesis and blood flow in early
pregnancy and maintaining uterine quiescence at mid-
and late pregnancy. Studies involving the infusion of
ADM receptor antagonist in early [31] and late [30]
gestation have also demonstrated the importance of
ADM in placentation and embryo development. The
infusion of the ADM2 receptor antagonist in late preg-
nancy produced similar results [53].
Both the levels of ADM peptide and Adm mRNA in
the placenta were lower in late pregnancy than mid-
pregnancy. The mRNA levels of Ramp3 also showed a
similar decline. To the best of our knowledge, this find-
ing has not been described before in the rat placenta. In
human, the concentrations of ADM mRNA in the pla-
centa were found to be greater at term than in the first
trimester [54]. The significance of these changes remains
an enigma. The mRNA levels of Adm, Crlr, Ramp1 and
Figure 4 Expression of Adm and its receptor components in the oviduct from early, mid- and late pregnant rat. Expression of Adm, Crlr,
Ramp1, Ramp2 and Ramp3 in the oviduct from nonpregnant rats and rats of different pregnancy stages. Data were presented as mean ± SEM. n
= 6-7.
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mid-pregnancy. This is related to the importance of
ADM in embryogenesis as ADM is involved in embryo-
nic invasion, proliferation, and differentiation, based on
the developmental expression patterns of ADM in the
rat and mouse embryos [55]. The Adm gene expression
in the placenta was higher while the peptide levels were
lower than those in the foetus in mid- and late
pregnancy, suggesting an increase in ADM release from
the placenta. Human placenta has indeed been proposed
to be the source of foetal circulating ADM as the ADM
concentration in the umbilical vein was higher than in
the artery [27].
The corpus luteum was studied instead of the entire
ovary because it contains most of the ADM, as reported
here and by Li et al. [14]. The mRNA levels of Adm,
Figure 5 ADM peptide levels in the uterus, foetus and placenta, corpus luteum, and oviduct. ADM peptide levels in the uterus (A) from
nonpregnant rats and rats of different pregnancy stages, in the foetus and placenta from mid- to late pregnant rats (B), and in the corpus
luteum (C), oviduct (D) from nonpregnant rats and rats of different pregnancy stages. Data were presented as mean ± SEM. n = 3-9.
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Page 8 of 12Figure 6 Immunocytochemical study of ADM in the uterus from nonpregnant and early pregnant rats. Immunocytochemical study of
ADM in the rat uterus from nonpregnant (A) and early pregnant rats (B-F) showing positive ADM immunoreactivity localized to the decidua (B),
the luminal epithelium (C), the embryo (asterisk, D), glandular epithelial cells (E) and endothelial linings of the blood vessels (F) of the uterus
from early pregnant rats.
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increased in late pregnancy compared with nonpreg-
nancy, pre-implantation and early pregnancy and ADM
peptide levels also increased at late pregnancy compared
with early and mid-pregnancy. These increases may be
related to the postulated roles of ADM in anti-luteolysis
[12] and the production of progesterone [14]. ADM
appears to play a double role in corpus luteum proges-
terone production in that it is inhibitory in early and
late pregnancy but stimulatory in mid-pregnancy (Li et
al. unpublished data). The stimulatory effect of ADM on
steroidogenesis has been reported in human granulosa-
lutein cells [13].
Conclusions
In summary, there is a spatio-temporal pattern for the gene
expression levels of Adm and its receptor components -
Crlr, Ramp1, Ramp2 and Ramp3, the ADM peptide con-
centration and localization in the rat female reproductive
system during gestation. In the oviduct, an increase in
ADM peptide was found only in the preimplantation stage
when the gametes/embryos were present in this part of the
reproductive tract. During early pregnancy, the contact of
embryo in the implantations sites upregulated ADM pep-
tide and mRNA expression. The increase was further
augmented in mid-pregnancy and similar increase was
found in the placentae and the expression was compara-
tively low in the foetuses. A dramatic increase in ADM
peptide and mRNA expression was also found in the cor-
pus luteum during mid- and late pregnancy. All these
changes suggest important roles for ADM in the mainte-
nance of pregnancy as well as embryogenesis.
Additional material
Additional file 1: Figure S1. Negative controls of ADM Immunocyto-
chemical study.
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